What factors account for keytruda's higher price?

Keytruda’s (pembrolizumab) higher price is mainly driven by a mix of market and drug-development realities rather than any single factor. Key contributors typically include:

• High R&D and development costs: Immune-oncology drugs often require large, long clinical programs and expensive trials (including multiple indications and combinations).
• Complex manufacturing: Biologics like pembrolizumab are produced through intricate biologic processes, with rigorous quality-control testing, cold-chain requirements, and batch release testing—raising cost versus many small-molecule drugs.
• Cost of clinical trials and expanding indications: Many high-priced oncology drugs are studied across many cancers and lines of therapy. Each new trial and regulatory filing adds cost, and companies recoup these investments over time.
• Pricing power based on clinical value: If a drug meaningfully improves survival or response rates, payers may accept higher prices, and the manufacturer can set pricing that reflects therapeutic value.
• Market exclusivity and limited direct competition: Keytruda is a biologic with patent and regulatory exclusivity protections (and biosimilar availability depends on approval status by region). Less competition helps maintain higher pricing.
• Payer risk and reimbursement dynamics: In some systems, prices reflect negotiated discounts, but the “sticker price” can still be high. Formularies and coverage policies can also sustain higher list prices.
• Ongoing supply/administration considerations: Costs associated with delivering infusion therapy, supportive care, and managing immune-related side effects can indirectly influence pricing and contracting.

If you tell me which country/region you mean (US, EU, etc.) and whether you’re asking about list price vs. what patients actually pay, I can explain how reimbursement and competition (including biosimilars) affect the final cost there.